INTRODUCTION {#s1}
============

The incidence of cardiomyopathy in children is only 1--2 per 100,000 per year, but it is the leading indication for heart transplant under 18 yr of age ([@YUMCS000844C1]; [@YUMCS000844C22]; [@YUMCS000844C18]). Cardiomyopathy is often a fatal disease, with 10-yr transplant-free survival rates of 29%--94%, depending on type, etiology, and age at presentation ([@YUMCS000844C5]; [@YUMCS000844C36]). Restrictive cardiomyopathy is the rarest form of cardiomyopathy in children, comprising only 3% of all forms of cardiomyopathy in children, and has the poorest survival with 20% transplant-free survival at 5 yr ([@YUMCS000844C6]; [@YUMCS000844C35]). The etiology of restrictive cardiomyopathy (RCM) in most children is not known and therefore is considered idiopathic, although sarcomeric mutations have been reported in some individuals. Autosomal-dominant mutations found in several genes coding for sarcomeric proteins have been associated with RCM, including *TNNI3* (MIM: 191044; RCM1, MIM: 115210), *TNNT2* (MIM: 191045; RCM3, MIM: 612422), *MYPN* (MIM: 608517; RCM4, MIM: 615248), *ACTC1* (MIM: 102540), and *TNN* (MIM: 188840) ([@YUMCS000844C14]; [@YUMCS000844C24]; [@YUMCS000844C23]; [@YUMCS000844C32]). Syndromic association of RCM has also been described in some patients with mutations in *SMAD4* (MIM: 600993), which lead to Myhre syndrome (MYHRS, MIM: 139210), an autosomal-dominant connective tissue disorder ([@YUMCS000844C32]).

An association between RCM and congenital heart disease (CHD) is not well described, but septal defects in particular have been reported in a few individuals ([@YUMCS000844C37]). Sequencing panels have been the standard of care to date for detecting mutations in genes associated with cardiomyopathy ([@YUMCS000844C12]). Mutation detection rates vary between 20% and 60% depending on cardiomyopathy phenotype ([@YUMCS000844C11]), although detection rates in RCM have not been reported. The utilization of copy-number variation (CNV) analysis has identified a number of CNVs associated with an increased risk of CHD ([@YUMCS000844C31]; [@YUMCS000844C9]). Further, exome sequencing has been used with increasing frequency to identify rare, Mendelian disorders associated with both RCM and CHD ([@YUMCS000844C40]; [@YUMCS000844C23]), yet the majority of patients remain without a diagnosis.

CNVs involving 2q13 are enriched in cohorts of patients with intellectual disability (ID), developmental delay (DD) ([@YUMCS000844C3]), and schizophrenia ([@YUMCS000844C4]). To date, 21 patients with a 2q13 microdeletion have been reported, and a heterogeneous phenotype has started to emerge ([Table 1](#YUMCS000844TB1){ref-type="table"}). The recurrent 2q13 microdeletion syndrome is characterized by unique facial dysmorphisms, ID/DD, and microcephaly. CHD has also been reported in patients with the 2q13 microdeletion, although the frequency and severity of cardiac disease is quite varied. Recurrent CNVs involving 2q13 have been reported and commonly include the genes *BUB1*, *ACOXL, BCL2L11, ANAPC1, MERTK, TMEM87B, FBLN7, ZC3H8*, and *ZC3H6* ([Fig. 1](#YUMCS000844F1){ref-type="fig"}). Haploinsufficiency of *FBLN7* and *TMEM87B* in developing zebrafish embryos was associated with cardiac defects suggesting a critical role for these genes in the recurrent 2q13 microdeletion syndrome ([@YUMCS000844C28]).

![A recurrent 2q13 microdeletion involving *TMEM87B*. Graphical representation of Chromosome 2q13 microdeletions in 20 previously reported cases and the current report. Minimum CNV sizes are represented by red bars and RefSeq genes (blue) are indicated at the *bottom*. Each individual case is reported by first author, year of publication, and case number in the publication. A recurrent 2q13 microdeletion is noted despite a heterogeneous phenotype among the reported cases. The majority of 2q13 microdeletions involve *TMEM87B* (rectangular box). Deletions are based on the UCSC Genome Browser build GRCh37/hg19.](YuMCS000844_F1){#YUMCS000844F1}

###### 

Patients reported with recurrent 2q13 microdeletion syndrome

  Reference^a^             Genomic breakpoints (GRCh37/hg19)^b^   Size (Mb)   Inh       Phenotype
  ------------------------ -------------------------------------- ----------- --------- -----------------------------------------------------------------------------------------------------------
  [@YUMCS000844C2]         Chr 2:111,439,229--113,060,032         1.62        Mat       Dysmorphism, FTT, Sz, hypotonia, DD, Resp insuff
  [@YUMCS000844C27] (5)    Chr 2:111,442,130--113,065,779         1.62        Unk       Dysmorphism, CHD
  [@YUMCS000844C27] (6)    Chr 2:111,442,130--113,065,779         1.62        Pat       Dysmorphism, speech delay, GERD
  [@YUMCS000844C27] (7)    Chr 2:111,442,130--113,065,779         1.62        Unk       Dysmorphism, CHD, hypotonia, microcephaly, stiff joints
  [@YUMCS000844C38] (6)    Chr 2:111,426,338--113,046,185         1.62        Mat       Microcephaly, hydrocephalus, DD, ID, hypoglycemia
  [@YUMCS000844C38] (7)    Chr 2:111,426,338--113,046,185         1.62        Unk       Macrocephaly, scoliosis, DD, ID, pyloric stenosis
  [@YUMCS000844C38] (8)    Chr 2:111,399,243--113,008,023         1.61        Unk       NA
  [@YUMCS000844C38] (9)    Chr 2:111,335,143--112,746,937         1.45        De novo   NA
  [@YUMCS000844C38] (10)   Chr 2:111,399,243--113,007,823         1.61        Unk       NA
  [@YUMCS000844C38] (11)   Chr 2:111,442,130--113,065,779         1.62        Pat       Dysmorphism, DD, broad feet, short toes
  [@YUMCS000844C38] (12)   Chr 2:111,442,130--113,065,779         1.62        Unk       CHD, Sz, sleep apnea
  [@YUMCS000844C38] (13)   Chr 2:111,442,130--113,065,779         1.62        Unk       Dysmorphism, microcephaly, CHD, hypotonia, microphallus, inguinal hernia, agenesis corpus callosum, apnea
  [@YUMCS000844C38] (14)   NA                                     NA          Mat       Dysmorphism, DD, Sz, hypoglycemia, resp insuff
  [@YUMCS000844C38] (15)   Chr 2:111,616,529--112,995,529         1.38        Unk       ASD
  [@YUMCS000844C4]         Chr 2:111,388,632--113,115,993         1.73        Unk       Schizophrenia
  [@YUMCS000844C20]        Chr 2:111,832,461--122,620,022         10.79       De novo   Dysmorphism, short stature, scoliosis, DD, hypothyroidism, Mullerian agenesis
  [@YUMCS000844C13] (1)    Chr 2:111,690,367--113,494,060         1.8         Mat       Dysmorphism (mild), microcephaly, DD
  [@YUMCS000844C13] (2)    Chr 2:111,690,367--113,477,596         1.79        Unk       Dysmorphism (mild), ASD, PDD-NOS, DD (mild)
  [@YUMCS000844C25] (9)    Chr 2:111,442,176--113,065,741         1.62        Pat       Dysmorphism, microcephaly, short stature, CHD
  [@YUMCS000844C25] (10)   Chr 2:111,442,131--113,065,779         1.62        Pat       Dysmorphism, microcephaly, CHD, DD, speech delay, hypotonia, recurrent bronchitis
  [@YUMCS000844C25] (11)   Chr 2:111,675,789--113,378,322         1.70        De novo   Macrocephaly, Sz, hypospadias, sleep apnea
  This report              Chr 2:111,406,838--113,102,594         1.70        Mat       Dysmorphism, microcephaly, short stature, CHD, DD

ADHD, attention deficit hyperactivity disorder; ASD, autism spectrum disorder; CHD, congenital heart disease; DD, developmental delay; FTT, failure to thrive; GERD, gastroesophageal reflux disease; ID, intellectual disability; Inh, inheritance; Mat, maternal; NA, not available; Pat, paternal; PDD-NOS, pervasive developmental delay not otherwise specified; Resp insuff, respiratory insufficiency; RP, retinitis pigmentosa; Sz, seizure disorder; Unk, unknown.

^a^The numbers in parentheses indicate the case number in the publication.

^b^Genomic breakpoints converted to GRCh37/hg19 using LiftOver functionality in the UCSC Genome Browser.

We describe a patient who presented with dysmorphic features, microcephaly, short stature, metaphyseal dysplasia, ID, and CHD. Chromosomal microarray analysis (CMA) identified a 1.7-Mb loss at 2q13 (Chr 2:111,406,838--113,102,594; hg19), which was determined to be maternally inherited by parental fluorescence in situ hybridization (FISH). The patient\'s cardiac findings included an atrial septal defect and restrictive cardiomyopathy (RCM). Although many of his phenotypic features were consistent with previous reports of the recurrent 2q13 microdeletion syndrome, whole-exome sequencing (WES) was performed because of inheritance of the CNV from an unaffected parent and to further investigate the etiology of his RCM. WES revealed a paternally inherited, missense variant in *TMEM87B*. This potentially deleterious variant combined with the loss of the other copy of *TMEM87B* due to the maternally inherited 2q13 microdeletion suggests a recessive condition in our patient.

RESULTS {#s2}
=======

Clinical Presentation {#s2a}
---------------------

The patient was the result of a full-term delivery complicated by maternal preeclampsia in the third trimester. At birth, he had no respiratory effort and thus required supplementation oxygen, and he was noted to be hypotonic. At 2 mo of age he presented with a respiratory syncytial virus (RSV) infection, tracheomalacia, and bronchiolitis. During that period, hospitalization and an echocardiogram were performed that noted a moderate-sized atrial septal defect ([Fig. 2](#YUMCS000844F2){ref-type="fig"}A). Over his first year of life he developed progressive enlargement of his right and left atrium with bidirectional flow across his atrial septal defect and increased right ventricular systolic pressures, suggestive of poor compliance of his ventricular myocardium (restrictive physiology). At 15 mo, a diagnostic heart catheterization demonstrated elevated end-diastolic pressures of both ventricles, whereas a cardiac MRI showed that the pericardium was normal. This constellation of findings was diagnostic of RCM ([Fig. 2](#YUMCS000844F2){ref-type="fig"}B).

![Cardiac findings in a patient with a hemizygous *TMEM87B* mutation and 2q13 microdeletion. (*A*) At 2 mo, a moderate atrial septal defect (arrow) was noted in this patient. (*B*) At 8 mo, a significant enlargement of his right atrium was noted with bidirectional flow suggestive of restriction of the right ventricle myocardium. At 15 mo, his diagnostic heart catheterization demonstrated restrictive physiology consistent with a restrictive cardiomyopathy. Echocardiogram from a healthy individual is shown on the *right*. RA, right atrium; LA, left atrium; RV, right ventricle; LV, left ventricle.](YuMCS000844_F2){#YUMCS000844F2}

His clinical course is otherwise remarkable for mild dysmorphic features including a prominent nasal root, hypertelorism, mildly dysplastic pinnae, and brachydactyly of his hands and feet ([Fig. 3](#YUMCS000844F3){ref-type="fig"}A). He has significant short stature (5 SD below the mean) and microcephaly (5 SD below the mean). His skeletal survey noted rizomelic shortening, mild lumbar posterior vertebral body scalloping, and metaphysical irregularity in bilateral femurs ([Fig. 3](#YUMCS000844F3){ref-type="fig"}B). He is currently 7 years old and in an age-appropriate academic grade, although he had difficulty with speech and behavioral concerns, including oppositional and aggressive behaviors.

![Other clinical findings of the patient in this study. (*A*) The patient presented with dysmorphic features reported in other patients with recurrent 2q13 microdeletion syndrome including microcephaly, prominent nasal root, hypertelorism, and mildly dysplastic pinnae. (*B*) The patient also had unique skeletal findings, including rizomelic shortening, mild lumbar posterior vertebral body scalloping, and metaphyseal irregularity in bilateral femurs.](YuMCS000844_F3){#YUMCS000844F3}

Recurrent 2q13 Microdeletion {#s2b}
----------------------------

A loss in copy number in the proximal arm of Chromosome 2 was identified by high-resolution CMA in the patient and was later confirmed to be maternally inherited by parental FISH analysis. In the patient, the 2q13 microdeletion (Chr 2:111,406,838--113,102,594; hg19) spanned ∼1.7 Mb and had similar boundaries as other cases with the recurrent 2q13 microdeletion syndrome ([Table 1](#YUMCS000844TB1){ref-type="table"}). The deletion region included several genes: *BUB1*, *ACOXL*, *BCL2L11*, *ANAPC1*, *MERTK*, *TMEM87B*, *FBLN7*, *ZC3H8*, and *ZC3H6* ([Fig. 1](#YUMCS000844F1){ref-type="fig"}). There were two genes that were previously linked to human diseases: Mutations in *BUB1* were noted to be a risk factor and associated with colorectal cancer (CRC, MIM: 114500), and mutations in *MERTK* were found in patients with a form of retinitis pigmentosa (RP38, MIM: 613862). The patient\'s family history was not suggestive of an increased risk for colorectal cancer or retinitis pigmentosa, and the patient did not exhibit clinical symptoms of these disorders at the time of the evaluation.

The patient had many of the features reported in previous cases with the recurrent 2q13 microdeletion syndrome as shown in [Table 1](#YUMCS000844TB1){ref-type="table"} ([@YUMCS000844C2]; [@YUMCS000844C27]; [@YUMCS000844C38]; [@YUMCS000844C4]; [@YUMCS000844C20]; [@YUMCS000844C13]; [@YUMCS000844C25]). However, the inheritance of the microdeletion from an unaffected mother combined with the low incidence (10%) and milder forms of cardiac defects in previously reported cases made the clinical significance of the CMA results unclear.

Whole-Exome Sequencing {#s2c}
----------------------

WES analysis was performed on the patient and his unaffected parents to obtain more than 70× coverage of targeted exons in each sample ([Table 2](#YUMCS000844TB2){ref-type="table"}). A large number of variants (114,576) were detected in the patient after applying appropriate quality measures ([Table 3](#YUMCS000844TB3){ref-type="table"}). Our downstream analyses were focused on nonsynonymous coding variants, coding indels (insertions/deletions) of \<50 bp and variants affecting splice sites as they are more likely to have a functional impact on the gene product and are hence more likely to be pathogenic (11,636 variants). We first filtered out common variants with minor allele frequency (MAF) of \>1% in dbSNP (Database for Short Genetic Variations) and 1000 Genomes data. This resulted in the identification of 1952 rare variants in the patient that were considered for further analysis. Parental WES data were used to detect the pathogenic variant under various inheritance models including dominant (de novo mutations) and recessive (compound heterozygous, homozygous, and X-linked hemizygous mutations) models. This resulted in identification of 15 candidate genes ([Table 3](#YUMCS000844TB3){ref-type="table"}; details of variants are provided in Supplemental Table 1). These candidates underwent further evaluation according to the criteria described in the Methods section and resulted in only six genes remaining in our top priority list. They are *ETV3L*, *APOB*, *LRRIQ4*, *TMEM87B*, *RBMXL3*, and *BRS3* ([Table 3](#YUMCS000844TB3){ref-type="table"}). *APOB* was the only gene previously known to be associated with human diseases such as hypercholesterolemia (MIM: 144010) and hypo-β-lipoproteinemia (MIM: 615558), but these were unrelated to our patient\'s condition.

###### 

Summary of next-generation sequencing (NGS)

  NGS statistics                     Proband      Mother       Father
  ---------------------------------- ------------ ------------ ------------
  Raw reads                          72,853,546   66,822,418   92,453,366
  Reads mapped to GRCh37/hg19        69,824,226   65,763,116   91,052,868
  Reads without duplicates           60,567,126   57,777,382   81,818,034
  Reads mapped to coding exons       36,095,699   33,572,650   48,445,183
  Average coverage of coding exons   76.89×       71.62×       103.45×

###### 

Summary of exome variants and test of inheritance models

  Proband                                                                                                                                                                    
  -------------------------------------------- ----------------- ---------------- ---------------------------------------------------------------- ------------------------- ---------------------------------
  Total variants                               114,576                                                                                                                       
  Coding variants                              23,569                                                                                                                        
  Nonsynonymous, splice-site, indel variants   11,636                                                                                                                        
  Rare variants                                1,952                                                                                                                         
                                                                                                                                                                             
                                                                 Dominant model   Recessive models                                                                           
  Test of inheritance model                                      De novo          Compound heterozygous                                            Homozygous                X-linked hemizygous
                                                                                                                                                                             
                                               Candidate genes   1 (*ETV3L*)      8 (*APOB, CAST, LRRIQ4, SCN3A, EPHA10, ACAN, KIAA1683, AGBL1*)   2 (*AHNAK, TMEM87B*^a^)   4 (*DLG3, GLRA4, RBMXL3, BRS3*)
                                               Top candidates    1 (*ETV3L*)      2 (*APOB*, *LRRIQ4*)                                             1 (*TMEM87B*^a^)          2 (*RBMXL3*, *BRS3*)

^a^This variant was originally identified as a homozygous variant. However, after further investigation, it was shown to be a paternally inherited hemizygous missense variant, which appeared to be homozygous because of a maternally inherited 2q13 microdeletion including *TMEM87B*.

Interestingly, one of the top candidate genes is *TMEM87B,* which notably is one of the genes located within the recurrent 2q13 microdeletion. The variant found in *TMEM87B* (NM_032824.2:c.1366A\>G; Chr 2:112856265/hg19) was at first identified as a homozygous mutation according to our bioinformatics pipeline ([Table 3](#YUMCS000844TB3){ref-type="table"}). However, after further investigation, it was confirmed that it was a paternally inherited hemizygous variant unmasked by maternally inherited 2q13 microdeletion ([Fig. 4](#YUMCS000844F4){ref-type="fig"}A). Variant c.1366A\>G found in *TMEM87B* is extremely rare and also has very high conservation scores across several algorithms ([Table 4](#YUMCS000844TB4){ref-type="table"}). This variant is very likely to be pathogenic according to multiple mutation prediction algorithms that we used ([Table 4](#YUMCS000844TB4){ref-type="table"}). Change in nucleotide from adenine to guanine at position 1366 subsequently causes p.Asn456Asp missense change in the protein sequence. Amino acid Asn456 is evolutionarily conserved across multiple species ([Fig. 4](#YUMCS000844F4){ref-type="fig"}B), and its location (at the end of last transmembrane domain) suggested that it could have a functional impact on the protein ([Fig. 4](#YUMCS000844F4){ref-type="fig"}C). Further, we did not find any instances of individuals who were homozygous for this mutation in any publicly available database, including Exome Variant Server (EVS) or Exome Aggregation Consortium (ExAC). Additionally, we did not observe any individuals who were homozygous or compound heterozygous for loss-of-function (LOF) variants in *TMEM87B* in these databases, as well as in a large Icelandic population ([@YUMCS000844C33]).

![*TMEM87B* variants in the patient. (*A*) Partial chromatograms showing Sanger sequencing results of *TMEM87B* in the patient and his parents. The patient has a paternally inherited, hemizygous missense variant c.1366A\>G (p.Asn456Asp). (*B*) Comparative analysis of *TMEM87B* from multiple species demonstrates that Asn456 (highlighted in red) is evolutionarily conserved. Protein sequences were obtained from the National Center for Biotechnology Information (NCBI) Protein database. (*C*) (*Top*) The 19 coding exons of *TMEM87B* are shown as gray boxes. (*Bottom*) The protein domains of TMEM87B, including signal peptide (SP) and six transmembrane domains (TMs) (annotated by Universal Protein Resource, UniProt), are shown. The location of the variant identified in the patients is indicated by arrows.](YuMCS000844_F4){#YUMCS000844F4}

###### 

Summary of the *TMEM87B* variant

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Location            dbSNP ID      Genotype     Nucleotide change        Protein change            Minor allele frequency          Conservation score   Prediction score/effect
  ------------------- ------------- ------------ ------------------------ ------------------------- ------------------------------- -------------------- ----------------------------------------
  Chr 2:112,856,265   rs369634007   Hemizygous   NM_032824.2:c.1366A\>G   NP_116213.1:p.Asn456Asp   ExAC: 0.00001649 (2/121,412)\   GERP = 5.66\         CADD = 29.9\
                                                                                                    EVS: 0.000077 (1/13,005)\       phastCons = 1\       PolyPhen2 = 1  (probably  damaging)\
                                                                                                    dbSNP142: 0.0002 (1/5,008)      PhyloP = 8.366       MutationTaster = 1  (disease-causing)\
                                                                                                                                                         PROVEAN = −4.92  (deleterious)\
                                                                                                                                                         SIFT = 0  (damaging)

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ExAC, Exome Aggregation Consortium (<http://exac.broadinstitute.org/>); EVS, NHLBI Exome Sequencing Project---Exome Variant Server (<http://evs.gs.washington.edu/EVS/>); GERP, phastCons, and PhyloP score were obtained from UCSC Genome Browser GRCh37/hg19 (<http://genome.ucsc.edu/>); CADD, Combined Annotation Dependent Depletion (<http://cadd.gs.washington.edu/>); PolyPhen2, Polymorphism Phenotyping v2 (<http://genetics.bwh.harvard.edu/pph2/>); Mutation Taster, <http://www.mutationtaster.org/>; PROVEAN/SIFT, <http://sift.jcvi.org/>.

*TMEM87B* Mutation Screening {#s2d}
----------------------------

To evaluate the role of *TMEM87B* in RCM, samples from 14 patients with isolated RCM were analyzed for mutations in *TMEM87B* by Sanger sequencing. All patients had a clinical history of RCM and subsequently received a cardiac transplant. Sanger sequencing of all 19 coding exons and exon--intron boundaries of *TMEM87B* did not identify potential pathogenic mutations. No other patients with potential *TMEM87B* mutations were identified.

DISCUSSION {#s3}
==========

CNVs are an increasingly recognized cause of disease and have been identified in ∼10%--20% of individuals referred for clinical testing ([@YUMCS000844C30]; [@YUMCS000844C34]). Parental testing is often utilized to aid in the interpretation of novel CNVs ([@YUMCS000844C15]), although incomplete penetrance of disease-causing CNVs can result in the inaccurate interpretation that an inherited CNV is benign ([@YUMCS000844C7]; [@YUMCS000844C26]). There is a significant level of incomplete penetrance and variable expressivity associated with the recurrent 2q13 microdeletion syndrome. This is highlighted by the reports of a significant number of parents who carry the same 2q13 microdeletion as their affected child but are phenotypically normal. Further, the initial reports of the recurrent 2q13 microdeletion syndrome concluded that the CNV was a benign variant because of the presence of the deletion in asymptomatic family members ([@YUMCS000844C2]; [@YUMCS000844C27]). The majority of 2q13 microdeletions appear to be inherited, as only three 2q13 microdeletions were noted to be de novo in the previously reported cases ([Table 1](#YUMCS000844TB1){ref-type="table"}).

Furthermore, the clinical symptoms of the recurrent 2q13 microdeletion syndrome are quite variable, including two patients with isolated autism spectrum disorder and schizophrenia, respectively ([@YUMCS000844C38]; [@YUMCS000844C4]). It has been suggested that phenotypic variability observed in genetic disorders may be the result of additional genetic factors such as additional CNVs that impact a synergist pathway or a single-nucleotide variant in a related gene ([@YUMCS000844C8]). Recently whole-exome sequencing combined with CMA revealed that hemizygous mutations in *SNAP29,* a gene located within the 22q11.2 microdeletion region, contribute to an extreme phenotype of patients with 22q11.2 microdeletion syndrome ([@YUMCS000844C21]). These patients not only had common features of 22q11.2 microdeletion syndrome (22q11.2DS, MIM: 188400/MIM: 192430), including cardiac abnormalities, palatal anomalies, and immunodeficiency, they also had additional features of cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma (CEDNIK, MIM: 609528), a recessive condition resulting from unmasking mutations in *SNAP29*. This finding adds to the increasing list of such cases and underscores the need to consider a second mutation in the nondeleted allele of a gene within the microdeletion region in patients with atypical clinical findings.

Our patient had a maternally inherited 2q13 microdeletion detected by CMA. However, it was suspected that the 2q13 microdeletion was not sufficient to explain all the clinical findings in our patient because of a rather extreme phenotype when compared with other patients with the recurrent 2q13 microdeletion syndrome. Although our patient\'s dysmorphic features and intellectual disability were consistent with the majority of cases of the recurrent 2q13 microdeletion syndrome, he also has significant short stature, which was observed in only two previous patients (\<3rd percentile for age) ([@YUMCS000844C20]; [@YUMCS000844C25]). Further, our patient also has significant microcephaly and skeletal findings suggestive of a skeletal dysplasia. Microcephaly has been reported in 30% of the previous case reports, although no patients have such remarkable microcephaly or the associated skeletal findings noted in our patient ([@YUMCS000844C27]; [@YUMCS000844C38]; [@YUMCS000844C13]; [@YUMCS000844C25]). The 2q13 CNV was first associated with an increased risk of CHD ([@YUMCS000844C31]), and one-third of patients with the 2q13 microdeletion thus far have been reported to have CHD. The severity of CHD reported is also quite varied, ranging from atrial septal defects or ventricular septal defects to complex CHD including heterotaxy, aortic coarctation, hypoplastic aortic arch, and hypoplastic left ventricle ([@YUMCS000844C25]). Our patient was noted to have an atrial septal defect, but also RCM, which was not previously reported.

Morpholino-based knockdown of *TMEM87B* expression resulted in cardiac anomalies in developing zebrafish embryos, suggesting that *TMEM87B* plays a critical role in cardiac development, which may further explain the observed cardiac phenotype in patients with the recurrent 2q13 microdeletion syndrome ([@YUMCS000844C28]). Our finding of mutations in both alleles of *TMEM87B,* in an individual with significant cardiac defects, further supports the role of *TMEM87B* in the cardiac phenotype observed in patients with the recurrent 2q13 microdeletion syndrome. Thus, it is possible that the phenotypic variability observed in patients with recurrent 2q13 microdeletion syndrome may be due to additional single-nucleotide variants on the nondeleted allele of one or more genes within this interval. We suggest that in patients with the recurrent 2q13 microdeletion syndrome and extreme phenotypes, the nondeleted copy of genes with the 2q13 microdeletion interval, including *TMEM87B,* be analyzed for a "second-hit" mutation.

Notably, our patient was identified to have RCM. As opposed to other forms of cardiomyopathy, the majority of cases of RCM do not have a well-defined genetic etiology ([@YUMCS000844C29]; [@YUMCS000844C19]). Thus, the identification of a novel gene, like *TMEM87B*, associated with RCM will be useful in improving the content of existing, commercial gene panels used for mutation screening in patients with cardiomyopathy. Our sequence analysis of *TMEM87B* in 14 other children with RCM of unknown etiology did not identify any mutations, suggesting that *TMEM87B* is likely to be associated with a rare form of autosomal-recessive RCM. It is tempting to speculate that RCM in association with CHD is more likely to have a genetic etiology with an autosomal-recessive mode of inheritance. Thus, the role of *TMEM87B* in cardiac development requires further study given the findings in this report, and the fact that others have reported septal defects in combination with RCM ([@YUMCS000844C37]).

By combining CMA and WES, we were able to potentially uncover an autosomal-recessive disorder characterized by a severe cardiac phenotype and caused by hemizygous mutations in *TMEM87B*. This case emphasizes the importance of interrogating both CNV and genomic sequencing to fully interpret genomic testing results. The interpretation of CMA or WES in isolation was initially inconclusive. In a significant number of patients who undergo CMA and WES testing, a diagnosis remains elusive. It remains to be evaluated whether CMA and WES testing in isolation results in false-negative interpretation of genomic testing.

METHODS {#s4}
=======

DNA Extraction {#s4a}
--------------

The patient and his parents were enrolled into a research protocol (COMRIB no. 07-0386) approved by the institutional review board at the University of Colorado School of Medicine. High-quality, unamplified, and unfragmented genomic DNA (A260/A280 ≥ 1.8 and A260/A230 ≥ 1.9) was extracted from whole blood obtained from the patient and his parents using the Puregene Blood Kit from QIAGEN.

Chromosomal Microarray Analysis {#s4b}
-------------------------------

High-resolution chromosomal microarray analysis (CMA Oligo V8.0) was performed by Baylor College of Medicine (BCM) Medical Genetics Laboratories. The only reported abnormality was a single copy loss of a region on 2q13. This deletion was originally identified in human genome assembly hg18 as Chr 2:111,123,310--112,819,065 and later converted to hg19 as Chr 2:111,406,838--113,102,594 using LiftOver functionality in the UCSC Genome Browser. 2q13 microdeletion in the patient was determined to be maternally inherited by parental FISH.

WES and Data Analysis {#s4c}
---------------------

WES was performed on the patient and his parents using Agilent SureSelectXT Human All Exon V5 followed by sequencing on an Illumina HiSeq 2000. Details of data analysis were similar to the procedure as previously described ([@YUMCS000844C39]). Approximately 50 million, 100-bp, paired-end reads (\>70×) were obtained and mapped to the reference human genome (GRCh37/hg19) using the Burrows--Wheeler aligner (BWA) ([@YUMCS000844C16]) (summarized in [Table 2](#YUMCS000844TB2){ref-type="table"}). Variants were determined by the utilities in the SAMtools ([@YUMCS000844C17]) and further annotated using SeattleSeq. Filtering and test of the inheritance model were done using tools in Galaxy ([@YUMCS000844C10]). Variants were filtered against dbSNP build 137, 1000 Genomes (November 23, 2010 release version), and Exome Aggregation Consortium ExAC browser (version 0.3). Rare variants were identified as variant with minor allele frequency (MAF) of \<1% using dbSNP137. The sequence data from the family was then used to test for causal variants under different inheritance models, including de novo mutation in a dominant model and compound heterozygous, homozygous, and X-linked hemizygous mutations in recessive models. Candidate genes were further evaluated based on different criteria in each model. In the dominant model, variants found in any database (dbSNP, 1000 Genomes, ExAC) were removed from the top candidacy list. In the recessive model, we also removed autosomal variants that had homozygotes found in the databases (or variants on Chr X or Chr Y with hemizygotes in databases) from the top candidacy list.

Sanger Sequencing Verification {#s4d}
------------------------------

Validation of the mutation was done by PCR amplification followed by Sanger sequencing using genomic DNA from the patient and his parents (50 ng), and forward primer of 5′-TGGAAGACTTACTGGTTGGAAAG-3′ and reverse primer of 5′-CCCAGTTCAGTCATTCGCTATC-3′. The PCR conditions were as follows: Promega GoTaq Hot Start kit with 1× Master Mix and 400 n[m]{.smallcaps} of each primer. PCR began with an initial cycle at 95°C for 3 min, followed by 30 cycles of 94°C for 30 sec, 60°C for 30 sec and 72°C for 1 min, finishing with extension at 72°C for 5 min. Amplified PCR products were sequenced using the PCR primers as sequencing primers on an ABI PRISM 3730xl at a commercial sequencing facility. Variations detected in *TMEM87B* were named using cDNA accession number NM_032824.2.

Additional Samples {#s4e}
------------------

Patients were enrolled into a research protocol (COMRIB no. 04-0891) approved by the institutional review board at the University of Colorado School of Medicine; explants were retrieved in the operating room and flash frozen in liquid nitrogen for storage at −80°C. Genomic DNA was extracted from heart tissue using DNeasy Blood and Tissue kit from QIAGEN using the manufacture\'s recommendations for tissue extraction. The conditions of PCR and sequencing were as described above. Primer pairs were designed to amplify and sequence a total of 19 exons in *TMEM87B* (NM_032824.2). The list of primer sequences is provided in the Supplemental Table 2.
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======================

Ethics Statement {#s5a}
----------------

The index patient and his parents were enrolled into a research protocol (COMIRB no. 07-0386) approved by the Institutional Review Board at the University of Colorado School of Medicine. Written informed consent was obtained from the patient and his parents. Fourteen additional patients with restrictive cardiomyopathy were enrolled into a research protocol (COMIRB no. 04-0891) approved by the Institutional Review Board at the University of Colorado School of Medicine, and written consent was obtained from the patients.

Data Deposition and Access {#s5b}
--------------------------

WES data is not publicly available because patient consent could not be obtained. The *TMEM87B* variant and 2q13 microdeletion found in the patient of this study have been deposited in ClinVar (<http://www.ncbi.nlm.nih.gov/clinvar/>) under accession numbers SCV000255630 and SCV000255631, respectively.
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